Phenytoin serum levels were compared in a crossover study of a new 300 mg capsule form and three 100 mg capsules administered once daily. The new 300 mg capsule was equivalent to three 100 mg capsules in efficacy of seizure control and maintenance of phenytoin serum levels. This standard 300 mg dose produced a grand mean drug serum level of 7.63 mcg/ml and was below 10 mcg/ml in 15 to 20 patients. The authors recommend monitoring of phenytoin serum levels and clinical response, to detect needed dosage adjustments for optimum therapeutic benefit from phenytoin and to avoid toxic side effects.
Get full access to this article
View all access options for this article.
References
1.
BuchthalF.SvensmarkO.SchillerP. J.: Clinical and Electroencephalographic Correlations with Serum Levels of Diphenylhydantoin, Arch. Neurol.2: 624–630 (June) 1960.
BuchananR. A.KindelA. W.GouletJr.SmithT. C.: The Metabolism of Diphenylhydantoin (Dilantin®) Following Once-daily Administration, Neurology22: 126–136 (Feb.) 1972.
4.
CocksD. A.CritchleyE. M. R.HaywardH. W.OwenV.MawerG. E.WoodcockB. G.: Control of Epilepsy with a Single Daily Dose of Phenytoin Sodium, Br. J. Clin. Pharmacol.2: 449–453 (Oct.) 1975.
5.
LoeserE. W.Jr.: Studies on Metabolism of Diphenylhydantoin (Dilantin®), Neurology11: 424–429, 1961.
6.
StrandjordR. E.JoharnnessenS. I.: One Daily Dose of Diphenylhydantoin for Patients with Epilepsy, Epilepsia15: 317–327, 1974.
7.
SvensmarkO.SchillerP. J.BuchthalF.: 5,5-Diphenylhydantoin (Dilantin®) Blood Levels after Oral or Intravenous Dosage in Man, Acta Pharmacol. Toxicol.16: 331–346, 1960.
8.
WilderB. J.StreiffR. R.HammerR. H.: Diphenylhydantoin Absorption, Distribution and Excretion: Clinical Studies, InWoodburyD. M.PenryJ. K.SchmidtR. R. (Eds): Antiepileptic Drugs, New York, Raven Press, pp. 137–148, 1972.
KuttH.: Diphenylhydantoin. Interactions with Other Drugs in Man, InWoodburyD. M.PenryJ. K.SchmidtR. R. (Eds): Antiepileptic Drugs, New York, Raven Press, pp. 169–180, 1972.
16.
KuttH.: Diphenylhydantoin. Relation of Plasma Levels to Clinical Control, InWoodburyD. M.PenryJ. K.SchmidtR. R. (Eds): Antiepileptic Drugs, New York, Raven Press, pp. 211–218, 1972.
17.
ArnoldK.GerberN.: The Rate of Decline of Diphenylhydantoin in Human Plasma, Clin. Pharmacol. Ther.11: 121–134, 1970.
18.
HooperW. D.TyrerJ. H.EadieM. J.: Plasma Diphenylhydantoin Levels in Australian Adults, Aust. N. Z. J. Med.4: 449–455, 1974.
19.
LundL.AlvanG.BerlinA.AlexandersonB.: Pharmacokinetics of Single and Multiple Doses of Phenytoin in Man. Eur. J. Clin. Pharmacol.7: 81–86, 1974.
20.
ReynoldsE. H.ChadwickD.GalbraithA. W.: One Drug (Phenytoin) in the Treatment of Epilepsy, Lancet1: 923–926, 1976.
LundL.: Effects of Phenytoin in Patients with Epilepsy in Relation to its Concentration in Plasma, InDaviesD. S.PrichardB. N. S. (Eds): Biological Effects of Drugs in Relation to Their Plasma Concentrations, London, Macmillan Co., pp. 227–238, 1973.
23.
LundL.: Anticonvulsant Effect of Diphenylhydantoin Relative to Plasma Levels. A Prospective Three-year Study in Ambulant Patients with Generalized Epileptic Seizures, Arch. Neurol.31: 289–294 (Nov.) 1974.